Ruhi Kamran

Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism

Charles E. Grimshaw, Andy Jennings, Ruhi Kamran et al. · PLoS ONE · 2016 · 62 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Discovery of tricyclic 5,6-dihydro-1H-pyridin-2-ones as novel, potent, and orally bioavailable inhibitors of HCV NS5B polymerase

Frank Ruebsam, Douglas E. Murphy, Chinh Van Tran et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 43 citations

Pharmacy, Medicinal Chemistry, Pharmacology +15

Pyrrolo[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase

Frank Ruebsam, Stephen E. Webber, Martin T. Tran et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 37 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +12

Novel HCV NS5B polymerase inhibitors derived from 4-(1′,1′-dioxo-1′,4′-dihydro-1′λ6-benzo[1′,2′,4′]thiadiazin-3′-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7′-substituents and initial pharmacokinetic assessments

Lian‐Sheng Li, Yuefen Zhou, Douglas E. Murphy et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 35 citations

Pharmacy, Medicinal Chemistry, Pharmacokinetics +16

Discovery of novel benzo[b][1,4]oxazin-3(4H)-ones as poly(ADP-ribose)polymerase inhibitors

Anthony R. Gangloff, Jason W. Brown, Ron de Jong et al. · Bioorganic & Medicinal Chemistry Letters · 2013 · 35 citations · Full text

Pharmacy, Chemistry, Medicinal Chemistry +10